Form 4: USANA Director Fuller Acquires Stock & RSUs

USANA Health Sciences Director Gilbert A. Fuller reported the acquisition of 1,058 shares of common stock and 1,058 restricted stock units on January 22, 2026.

Summary

• Director Gilbert A. Fuller acquired 1,058 shares of USANA Health Sciences Inc. common stock on January 22, 2026.
• This acquisition was a result of the exercise or conversion of derivative securities, specifically Restricted Stock Units (RSUs), as indicated by transaction code 'M'.
• On the same date, Fuller also acquired 1,058 Restricted Stock Units (RSUs), also under transaction code 'M'.
• Following these transactions, Fuller directly beneficially owns 1,058 shares of common stock.
• Fuller also directly beneficially owns 1,057 Restricted Stock Units.
• Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
• The Restricted Stock Units have a vesting schedule of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.

Sentiment

Score: 7

Explanation: The acquisition of common stock and a new grant of Restricted Stock Units by a director is generally a positive signal, indicating continued commitment and alignment with shareholder interests. The minor discrepancy in RSU beneficial ownership is noted but does not significantly detract from the overall positive sentiment of insider equity acquisition.

Positives

• The acquisition of common stock and a new grant of Restricted Stock Units by a director indicates continued alignment of interests with shareholders.
• The grant of new Restricted Stock Units provides a long-term incentive for the director, tying their compensation to future company performance.

Negatives

• The filing contains a minor discrepancy where 1,058 Restricted Stock Units were reported as acquired, but the beneficial ownership following the transaction is stated as 1,057, implying a net reduction of one RSU despite the acquisition.

Future Outlook

The director's future compensation is tied to the company's performance through the vesting schedule of the Restricted Stock Units, with tranches scheduled to vest through April 2026.

Industry Context

This is a routine insider transaction filing, common for directors receiving equity compensation in publicly traded companies. It reflects standard corporate governance practices for aligning management and director interests with shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units as part of director compensation is a common practice across various industries, including the health sciences sector, aligning director incentives with long-term shareholder value.
• The vesting schedule, typically over several quarters or years, is standard for equity compensation to encourage sustained performance and retention.

Related Party Transactions

• The acquisition of common stock and Restricted Stock Units by Director Gilbert A. Fuller from USANA Health Sciences Inc. constitutes a related party transaction, as it involves a company insider receiving equity compensation from the issuer.

Stakeholder Impact

• Shareholders: The director's increased equity stake aligns their interests more closely with shareholders, potentially fostering decisions that enhance long-term shareholder value.

Next Steps

• Future vesting of the remaining Restricted Stock Units on October 23, 2025, January 22, 2026, and April 23, 2026.
• Subsequent Form 4 filings will be required for future transactions or vesting events by the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director acquired common stock through RSU vesting and received a new RSU grant. While it signals continued alignment of interests, it does not present new fundamental information about the company's operational or financial performance that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

USANA Health Sciences, USNA, Gilbert A. Fuller, Form 4, Insider Transaction, Restricted Stock Units, Common Stock, Director Compensation, Equity Grant